Clearbridge Health associate Biolidics lodges prelim prospectus

SINGAPORE (Nov 26): Biolidics, a cancer diagnostic solutions developer and an associate company of Clearbridge Health, on Friday lodged a preliminary prospectus for a planned initial public offering (IPO) on the Singapore Exchange's Catalist board.

Biolidics, incorporated as Clearbridge Biomedics in 2009, specialises in developing cell enrichment systems that can be combined with other analytical tests for cancer diagnosis, prognosis and treatment selection and monitoring.

Biolidics’ flagship product is the ClearCell FX1 System, a fully automated in vitro diagnostic medical device that separates and enriches cancer cells from blood to perform liquid biopsies.

---

Related Stories

• Biolidics to issue 98.5 mil shares at subscription price of 1.19 cents per share
• Biolidics raises $1.5 million from investor
• Biolidics raising $1.5 million by issuing new shares to investor from China

---